

FORM PTO-1449
(Modified)U.S. Department of Commerce
Patent and Trademark Office

Attorney Docket No.: CUTLER-06326

Serial No.: 09/899,412

INFORMATION DISCLOSURE STATEMENT BY APPLICANT
(Use Several Sheets If Necessary)

Applicant: Neal R. Cutler

Filing Date: 07/05/01

Group Art Unit: 1615

(37 CFR § 1.98(b))

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Serial / Patent Number	Issue Date	Applicant / Patentee	Class	Subclass	Filing Date
RMJ	1	4,389,393	6/21/83	Schor <i>et al.</i>	424	19	3/26/82
	2	4,650,810	3/17/87	Bays <i>et al.</i>	514	415	1/26/83
	3	4,914,125	4/03/90	Baldinger <i>et al.</i>	514	520	7/06/89
	4	4,916,125	4/10/90	Herrling <i>et al.</i>	514	89	7/11/89
	5	4,933,367	6/12/90	Wolff <i>et al.</i>	514	570	7/10/86
	6	4,963,367	10/16/90	Ecanow	424	485	12/15/87
	7	4,994,483	2/19/91	Oxford <i>et al.</i>	514	415	11/30/89
	8	5,006,342	4/09/91	Cleary <i>et al.</i>	424	445	2/10/89
	9	5,021,428	6/04/91	Carr <i>et al.</i>	514	317	11/17/89
	10	5,051,426	9/24/91	Parnell	514	263	3/27/90
	11	5,200,413	4/06/93	King <i>et al.</i>	514	299	8/05/91
	12	5,242,949	9/07/93	Goldberg <i>et al.</i>	514	652	3/13/92
	13	5,248,684	9/28/93	Suzuki <i>et al.</i>	514	299	5/21/91
	14	5,273,759	12/28/93	Simmons	424	465	9/17/92
	15	5,288,498	2/22/94	Stanley <i>et al.</i>	424	440	9/05/89
	16	5,317,103	5/31/94	Baker <i>et al.</i>	544	367	7/16/92
	17	5,364,863	11/15/94	Cohen <i>et al.</i>	514	304	4/26/93
	18	5,399,574	3/21/95	Robertson <i>et al.</i>	514	339	6/06/91
	19	5,434,154	7/18/95	Smith <i>et al.</i>	514	249	4/26/94
	20	5,441,969	8/15/95	Axelsson <i>et al.</i>	514	338	12/22/93
	21	5,464,864	11/07/95	King <i>et al.</i>	514	468	6/17/92
	22	5,466,699	11/14/95	Robertson <i>et al.</i>	514	323	12/05/94
	23	5,468,768	11/21/95	Cipollina <i>et al.</i>	514	415	1/06/94
	24	5,487,898	1/30/96	Lu <i>et al.</i>	424	435	2/07/94
	25	5,491,148	2/13/96	Berger <i>et al.</i>	514	305	4/26/91
	26	5,494,910	2/27/96	North <i>et al.</i>	514	233.5	10/14/93
	27	5,637,611	6/10/97	King <i>et al.</i>	514	468	5/15/95
	28	5,672,356	9/30/97	Rault <i>et al.</i>	424	468	9/21/94
	29	5,855,907	1/05/99	Peyman	424	434	3/24/97
	30	5,877,183	3/02/99	Cincotta	514	288	6/06/97
	31	5,891,885	4/06/99	Caruso	514	289	10/24/96
	32	5,939,425	8/17/99	Caruso	514	289	5/19/97
	33	5,942,251	8/24/99	Merkus	424	493	4/17/98

Examiner:

Date Considered:

10/23/03

EXAMINER:

Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449
(Modified)U.S. Department of Commerce
Patent and Trademark Office

Attorney Docket No.: CUTLER-06326

Serial No.: 09/899,412

INFORMATION DISCLOSURE STATEMENT BY APPLICANT
(Use Several Sheets If Necessary)

Applicant: Neal R. Cutler

(37 CFR § 1.98(b))

Filing Date: 07/05/01

Group Art Unit: 1615

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Serial / Patent Number	Issue Date	Applicant / Patentee	Class	Subclass	Filing Date
RMG	34	5,955,502	9/21/99	Hansen <i>et al.</i>	514	558	3/27/97
	35	6,010,719	1/04/00	Remon <i>et al.</i>	424	464	10/16/97
	36	6,077,539	6/20/00	Plachetka <i>et al.</i>	424	474	11/10/97
	37	6,103,218	8/15/00	Brucker <i>et al.</i>	424	45	4/23/97
	38	6,139,819	10/31/00	Unger <i>et al.</i>	424	9.52	10/17/97
	39	6,197,331	3/06/01	Lerner <i>et al.</i>	424	448	7/24/97
	40	6,200,604	3/13/01	Pather <i>et al.</i>	424	466	6/08/99
	41	6,221,392	4/24/01	Khankari <i>et al.</i>	424	464	12/16/99

OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)

RMG	42	Goodman and Gilman's "The Pharmaceutical Basis of Therapeutics", 8th ed., McGraw-Hill, Inc. (1990), pp. 944-947					
	43	Becker, "Migraine-associated symptoms: Clinical significance and management," <i>Can J Clin Pharmacol</i> 6 (Suppl A):15A-19A (1999)					
	44	Kiechel, "The Bioavailability and Kinetics of Dihydroergotamine" in Fitacha (Ed.); <i>Neuester Scand Der Dihydrergot Forschung</i> . Stuttgart Georg Thiema: 32-46 (1984)					
	45	Migranal (dihydroergotamine mesylate, USP) Nasal Spray Information, Novartis Pharmaceuticals Company, Inc. Publication 30721901, 1997					
	46	D.H.E. 45 (dihydroergotamine mesylate) Injection, USP Information, Novartis Pharmaceuticals Company, Inc., Publication 30220906, 1998					
	47						
	48						
	49						
	50						
	51						
	52						
	53						
	54						
	55						
	56						
	57						
	58						
	59						
	60						
	61						
	62						

Examiner:

Date Considered:

10/23/03

EXAMINER:

Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.